EUCTR2013-004662-33-AT进行中（未招募）1 期
JUNIPER: A Randomized Phase 3 Study of Abemaciclib plus Best Supportive Care versus Erlotinib plus Best Supportive Care in Patients with Stage IV NSCLC with a Detectable KRAS Mutation Who Have Progressed After Platinum Based Chemotherapy
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •The participants must have confirmed diagnosis of stage IV non-small cell lung cancer (NSCLC) according to the American Joint Committee on Cancer Staging Handbook.
- •Determined to have detectable mutations in codons 12 or 13 of the KRAS oncogene by an investigational assay at the Study JPBK central laboratory. A KRAS positive mutation result in codons 12 or 13 of the KRAS Oncogene from tumor tissue per local laboratory will be permitted on no more than 10% of the randomized patients;
- •The participant must have progressed after platinum-based chemotherapy (with or without maintenance therapy) AND have received one other additional therapy which may include an immune checkpoint inhibitor or other anti-cancer therapy for advanced and/or metastatic disease OR is judged by the physician as ineligible for further standard second-line chemotherapy. Prior adjuvant or neoadjuvant therapy for an earlier stage of NSCLC counts as an appropriate line of therapy in case the patient progressed within 6 months of completing the platinum-based adjuvant or neoadjuvant therapy.
- •Have measureable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
- •Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
- •Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and investigational therapy) for at least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents prior to receiving study drug.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 180
排除标准
- •Have received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agent, respectively.
- •Have a personal history of any of the following conditions: presyncope or syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
- •Have the presence of unstable central nervous system (CNS) metastasis. History of CNS metastasis or stable CNS metastases is allowed (no longer requiring active therapy such as steroid medications). Participants with a history of CNS metastases must have a brain scan (for example, magnetic resonance imaging) within 28 days of randomization to document stability, even if there have been no changes in symptoms.
研究者
相似试验
进行中（未招募）
1 期
A Study of Abemaciclib in Participants With Previously Treated Lung CancerEUCTR2013-004662-33-PLEli Lilly and Company450
进行中（未招募）
1 期
A Study of abemaciclib in Participants With Previously Treated Lung Canceron Small Cell Lung CancerMedDRA version: 19.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 100000004864EUCTR2013-004662-33-DEEli Lilly and Company450
进行中（未招募）
1 期
A Phase 1b/2 Study of Abemaciclib Plus Chemotherapy and/or Chemoimmunotherapy in Pediatric and Young Adult Patients with Relapsed/Refractory Solid TumorsRelapsed/Refractory Solid TumorsCTIS2023-506778-11-00Eli Lilly & Co.37
已完成
3 期
JUNIPER : A randomized Phase 3 study of abemaciclib plus best supportive care versus erlotinib plus best supportive care in patients with Stage IV NSCLC with a detectable KRAS mutation who have progressed after platinum-based chemotherapyon Small Cell Lung CancerJPRN-jRCT2080222632Eli Lilly Japan K.K.
进行中（未招募）
1 期
Study of Abemaciclib with Pembrolizumab in Patients with Stage IV Lung Cancer or Breast CancerStage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast CancerMedDRA version: 18.1Level: PTClassification code 10006202Term: Breast cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: LLTClassification code 10025055Term: Lung cancer non-small cell stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-005156-94-ESilly S.A.75